AbbVie Inc. Common Stock (ABBV)

About ABBV

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to…

Sector

Health Care

Industry

Biotechnology: Pharmaceutical Preparations

Employees

57,000

Website

www.abbvie.com/

Fundamentals

1-day range

$255.08$259

Market cap

$430.95B

P/E (trailing)

70.24

P/E (forward)

15.69

EPS (trailing)

$3.56

Dividend yield

4.47%

Beta

0.22

Avg. volume

6.58M

Ex-dividend date

July 15, 2026

Dividend pay date

August 14, 2026

Forecasts

29 analyst ratings

AbbVie Inc. Common Stock Competitors

Chosen by industry and closest market cap.

• ABBV

  AbbVie Inc. Common Stock

  $255.56

  ▼ 1.01%
  Market cap $430.95BP/E 70.24
  $190.75$267.47
• MRK

  Merck & Company Inc. Common Stock (new)

  $148.32

  ▼ 0.82%
  Market cap $317.05BP/E 103.86
  $77.58$156.92
• NVS

  Novartis AG Common Stock

  $153.79

  ▼ 0.56%
  Market cap $294.26BP/E 21.95
  $96.03$131.5
• AZN

  AstraZeneca PLC Ordinary Shares

  $162.69

  ▼ 1.11%
  Market cap $249.78BP/E 23.44
  $10,784$15,730
• JNJ

  Johnson & Johnson Common Stock

  $268.02

  ▲ 0.85%
  Market cap $619.30BP/E 29.93
  $173.33$276.47
• NVO

  Novo Nordisk A/S Common Stock

  $45.6

  ▼ 1.43%
  Market cap $203.55BP/E 11.40
  $224.25$409.95
• ABT

  Abbott Laboratories Common Stock

  $112.42

  ▲ 0.74%
  Market cap $186.81BP/E 35.52
  $81.97$137.49

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• AbbVie Submits EMA Application For SKYRIZI Subcutaneous Induction In Adults With Moderately To Severely Active Crohn's Disease, Backed By Phase 3 AFFIRM Data
  benzinga · 8/27/2026
• AbbVie Submits EMA Application For SKYRIZI Subcutaneous Induction In Adults With Moderately To Severely Active Crohn's Disease, Backed By Phase 3 AFFIRM Data
  Benzinga · 8/27/2026
• If You Invested $100 In AbbVie Stock 10 Years Ago, You Would Have This Much Today
  Benzinga · 8/26/2026
• TG Therapeutics: Briumvi's Peak May Be Far Away (Rating Upgrade)
  SeekingAlpha · 8/26/2026
• AbbVie Still Has Room To Run
  SeekingAlpha · 8/24/2026
• Sanofi: Trump's Vaccine Policy Won't Break The Story
  SeekingAlpha · 8/24/2026
• Best Dividend Kings: August 2026
  SeekingAlpha · 8/24/2026
• Wall Street Week Ahead
  SeekingAlpha · 8/23/2026
• Lilly's Multiple Assumes Less Growth Than You Think
  Yahoo · 8/21/2026

• Susan E. Quaggin · June 30, 2026 · Grant

  62 @ $251.64
• Edward J. Rapp · June 30, 2026 · Grant

  134 @ $251.64
• Susan E. Quaggin · May 8, 2026 · Grant

  1.1K
• Jennifer L. Davis · May 8, 2026 · Grant

  1.1K
• Melody B. Meyer · May 8, 2026 · Grant

  1.1K
• William H.l. Burnside · May 8, 2026 · Grant

  1.1K
• Brett J. Hart · May 8, 2026 · Grant

  1.1K
• Rebecca B. Roberts · May 8, 2026 · Grant

  1.1K
• Thomas C. Freyman · May 8, 2026 · Grant

  1.1K
• Frederick H. Waddell · May 8, 2026 · Grant

  1.1K
• Thomas J. Falk · May 8, 2026 · Grant

  1.1K
• Edward J. Rapp · May 8, 2026 · Grant

  1.1K
• Roxanne S. Austin · May 8, 2026 · Grant

  1.1K
• Susan E. Quaggin · March 31, 2026 · Grant

  71 @ $217.49
• Alpern Robert J · March 31, 2026 · Grant

  35 @ $217.49

Institutional Ownership

March 31, 2026

Total shares held

1.19B

Total value held

$248.47B

Institutional holders

4004